Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.460 +0.040 (+1.65%)
Streaming Delayed Price Updated: 3:31 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,209,922
Open 2.400
Bid (Size) 2.450 (16,500)
Ask (Size) 2.460 (13,100)
Prev. Close 2.420
Today's Range 2.360 - 2.620
52wk Range 1.639 - 9.700
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗
Iovance has a long way to go to get to a break-even point, but the company has been showing progress. 
Via The Motley Fool
News headline image
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
Wall Street may be overestimating these companies' potential. 
Via The Motley Fool

Performance

YTD
-68.4%
-68.4%
1 Month
+6.0%
+6.0%
3 Month
-1.6%
-1.6%
6 Month
+34.4%
+34.4%
1 Year
-70.8%
-70.8%

More News

Read More
News headline image
Top movers in Thursday's session ↗
Via Chartmill
News headline image
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026
Via AB Newswire
Why Are IOVA Shares Rising Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Gapping stocks in Thursday's session ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via FinancialNewsMedia
News headline image
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
Via MarketMinute
Topics Intellectual Property Workforce
News headline image
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health ↗
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? ↗
Via The Motley Fool
News headline image
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
Via The Motley Fool
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.460
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 11/18/25 03:31 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 750.92M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 751M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.